drugset / Trial / NCT06010004
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: * screening and lead-in period: up to 4 weeks * treatment period: 52 weeks, including 20 weeks of dose escalation, and * safety follow-up period: 2 weeks.
Timeline
- Start
- 2023-09-28
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 3 mg | Oral |
| Subject | Orforglipron | Small molecule | 12 mg | Oral |
| Subject | Orforglipron | Small molecule | 36 mg | Oral |